Healthcare Industry News: HSMN NewsFeed
News Release - February 21, 2018
Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR(R)BRIDGEWATER, N.J., Feb. 21, 2018 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals has launched memantine hydrochloride extended-release capsules, the company's AB-rated equivalent for Namenda XR®, in 7 mg, 14 mg, 21 mg and 28 mg strengths. The product is manufactured here in the United States in the company's recently expanded Brookhaven, New York facility.
Annual U.S. sales of Namenda XR® were $929 million, according to December 2017 QuintilesIMS market data.
Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia and Europe, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.
Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) announced on October 17, 2017 that they have entered into a definitive business combination agreement with the resulting combined company expected to create the 5th largest generics business (by gross revenue) in the United States. The transaction is expected to close in the first half of 2018.
For more information, visit amneal.com.
All trademarks listed in this release are property of their respective owners.
Source: Amneal Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAmneal Announces Favorable Ruling Regarding Patent Validity for Zomig(R) (zolmitriptan) Nasal Spray
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary(R)
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States